|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng R, Zeng H, Zhang S, Chen T and Chen
W: National estimates of cancer prevalence in China, 2011. Cancer
Lett. 370:33–38. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kanwar SS, Poolla A and Majumdar AP:
Regulation of colon cancer recurrence and development of
therapeutic strategies. World J Gastrointest Pathophysiol. 15:1–9.
2012. View Article : Google Scholar
|
|
4
|
Meyerhardt JA and Mayer RJ: Systemic
therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gupta SC, Sung B, Prasad S, Webb LJ and
Aggarwal BB: Cancer drug discovery by repurposing: Teaching new
tricks to old dogs. Trends Pharmacol Sci. 34:508–517. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rhodes DR, Ateeq B, Cao Q, Tomlins SA,
Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE,
Bhojani MS, et al: AGTR1 overexpression defines a subset of breast
cancer and confers sensitivity to losartan, an AGTR1 antagonist.
Proc Natl Acad Sci USA. 106:pp. 10284–10289. 2009, View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gaedcke J, Grade M, Jung K, Camps J, Jo P,
Emons G, Gehoff A, Sax U, Schirmer M, Becker H, et al: Mutated KRAS
results in overexpression of DUSP4, a MAP-kinase phosphatase, and
SMYD3, a histone methyltransferase, in rectal carcinomas. Genes
Chromosomes Cancer. 49:1024–1034. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Graudens E, Boulanger V, Mollard C,
Mariage-Samson R, Barlet X, Grémy G, Couillault C, Lajémi M,
Piatier-Tonneau D, Zaborski P, et al: Deciphering cellular states
of innate tumor drug responses. Genome Bio. 7:R192006. View Article : Google Scholar
|
|
10
|
Hong Y, Downey T, Eu KW, Koh PK and Cheah
PY: A ‘metastasis-prone’ signature for early-stage mismatch-repair
proficient sporadic colorectal cancer patients and its implications
for possible therapeutics. Clin Exp Metastasis. 27:83–90. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kaiser S, Park YK, Franklin JL, Halberg
RB, Yu M, Jessen WJ, Freudenberg J, Chen X, Haigis K, Jegga AG, et
al: Transcriptional recapitulation and subversion of embryonic
colon development by mouse colon tumor models and human colon
cancer. Genome Bio. 8:R1312007. View Article : Google Scholar
|
|
12
|
Ki DH, Jeung HC, Park CH, Kang SH, Lee GY,
Lee WS, Kim NK, Chung HC and Rha SY: Whole genome analysis for
liver metastasis gene signatures in colorectal cancer. Int J
cancer. 121:2005–2012. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cancer Genome Atlas Network: Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. J Natl Cancer
Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang HJ, Neven P, Drijkoningen M,
Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F,
Vergote I and Christiaens MR: Association between tumour
characteristics and HER-2/neu by immunohistochemistry in 1362 women
with primary operable breast cancer. J Clin Path. 58:611–616. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khan K, Cunningham D and Chau I: Targeting
angiogenic pathways in colorectal cancer: Complexities, challenges
and future directions. Curr Drug Targets. 18:56–71. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Antonov A, Agostini M, Morello M, Minieri
M, Melino G and Amelio I: Bioinformatics analysis of the serine and
glycine pathway in cancer cells. Oncotarget. 5:11004–11013. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang Y, Wu J, Cai J, He Z, Yuan J, Zhu X,
Li Y, Li M and Guan H: PSAT1 regulates cyclin D1 degradation and
sustains proliferation of non-small cell lung cancer cells. Int J
Cancer. 136:E39–E50. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim YH, Jung WH and Koo JS: Expression of
metabolism-related proteins in invasive lobular carcinoma:
Comparison to invasive ductal carcinoma. Tumor Bio. 35:10381–10393.
2014. View Article : Google Scholar
|
|
20
|
Martens JW, Nimmrich I, Koenig T, Look MP,
Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM,
Portengen H, et al: Association of DNA methylation of phosphoserine
aminotransferase with response to endocrine therapy in patients
with recurrent breast cancer. Cancer Res. 65:4101–4117. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De Marchi T, Timmermans MA, Sieuwerts AM,
Smid M, Look MP, Grebenchtchikov N, Sweep FCGJ, Smits JG, Magdolen
V, van Deurzen CHM, et al: Phosphoserine aminotransferase 1 is
associated to poor outcome on tamoxifen therapy in recurrent breast
cancer. Sci Rep. 7:20992017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vié N, Copois V, Bascoul-Mollevi C, Denis
V, Bec N, Robert B, Fraslon C, Conseiller E, Molina F, Larroque C,
et al: Overexpression of phosphoserine aminotransferase PSAT1
stimulates cell growth and increases chemoresistance of colon
cancer cells. Mol Cancer. 7:142008. View Article : Google Scholar : PubMed/NCBI
|
